comparemela.com

Vince Wacher News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Theriva Biologics, Inc (NYSE:TOVX) Q4 2023 Earnings Call Transcript

Theriva Biologics, Inc. beats earnings expectations. Reported EPS is $-0.34, expectations were $-0.41. Theriva Biologics, Inc.

United statesSteven shallcrossTheriva biologicsManel cascalloChris calabreseVince wacherJames molloyAlliance global partnersWashington universityProduct development of theriva biologicsUniversity of pennsylvaniaAlbumin shield technologyTheriva biologics incExchange commissionSociety for immunotherapy of cancer annual meetingData monitoring committee

Theriva Biologics, Inc (NYSE:TOVX) Q3 2023 Earnings Call Transcript

Operator: Greetings, and welcome to the Theriva Biologics, Inc. 2023 Third Quarter Operational Highlights and Financial Results.

United statesManel cascalloVince wacherSteve shallcrossJames molloyManel cascallTheriva biologicsRicard mesiaWashington universityAlbumin shield technologyProduct development of theriva biologicsUniversity of pennsylvaniaCatalan institute of oncologyExchange commissionEuropean society for medical oncology annual congressAlliance global partners

Theriva Biologics, Inc (ASE:TOVX) Q2 2023 Earnings Call Transcript

Operator: Ladies and gentlemen, good morning, and welcome to the Theriva Biologics, Inc. 2023 Second Quarter Earnings Conference Call.

United statesComunidad autonoma de catalunaJames molloyChris calabreseManel cascallSteven shallcrossRamon alemanyVince wacherTheriva biologicsWashington universityVirotherapy groupAlliance global partnersProduct development of theriva biologicsCatalan institute of oncologyTheriva biologics incUniversity of leeds

Theriva Biologics (TOVX) Q3 2022 Earnings Call Transcript

Theriva Biologics (NYSE:NYSE:TOVX) Q3 2022 Earnings Conference Call November 10, 2022 08:30 ET Company Participants Chris Calabrese - Investor Relations Steven Shallcross - Chief Executive.

Frank tufaroVince wacherTheriva biologics europeChris calabreseTheriva biologicsManel cascallSteven shallcrossJim molloyExchange commissionCompany participantsProduct developmentAlliance global partnersProduct development of theriva biologicsConference call novemberChief financialSynthetic biologics

Synthetic Biologics, Inc (SYN) CEO Steven Shallcross on Q1 2022 Results - Earnings Call Transcript

Synthetic Biologics, Inc. (NYSE:NYSE:SYN) Q1 2022 Earnings Conference Call May 16, 2022, 09:00 AM ET Company Participants Dean Schwartz - LifeSci Advisors, IR Steven Shallcross - CEO and.

United statesSouth koreaJason mccarthyFrank tufaroVince wacherLeland gershellManel cascalloJo anne leeSteven shallcrossManuel hidalgoJim molloyCompany participantsProduct development of synthetic biologicsAlliance global partnersUniversity at leedsMeeting of the american society gene

vimarsana © 2020. All Rights Reserved.